Dr. Lawrence J. Singerman, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Wayne State University School of Medicine (1969)
- Years since graduation
- 57
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 542
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1969Medical school: Wayne State University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
OH license 35-03-2379
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University of Miami (2,377 clinicians)
- Retina Associates of Cleveland, Inc. (19 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 542
- Services billed
- 18,799
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 6,960 | 22 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 1,920 | 70 |
| Imaging of retina | 1,262 | 475 |
| Injection, aflibercept, 1 mg | 1,166 | 148 |
| Established patient problem focused exam of visual system | 1,068 | 296 |
| Injection of drug into eye | 1,012 | 228 |
| Established patient complete exam of visual system | 404 | 370 |
| Photography of the retina | 403 | 289 |
| Unclassified drugs | 329 | 79 |
| Extended exam of the back part of the eye with optic nerve drawing | 161 | 144 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 28 payments worth $815 in total to this clinician.
| Genentech USA, Inc. | $255 |
|---|---|
| AbbVie Inc. | $196 |
| Regeneron Healthcare Solutions, Inc. | $184 |
| Apellis Pharmaceuticals, Inc. | $117 |
| Ani Pharmaceuticals, Inc. | $36.31 |
| Baxter Healthcare | $26.93 |
| Food and Beverage | $788 |
|---|---|
| Debt forgiveness | $26.93 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Baxter Healthcare Jan 9, 2025 | Debt forgiveness in-kind | $26.93 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $587,681 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-R…
Apellis Pharmaceuticals, Inc. - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Apellis Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.